China Bariatric Surgery Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The China bariatric surgery market includes a range of surgical interventions for obesity and related metabolic conditions, with the primary procedure categories being sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), gastric banding, and gastric balloon procedures. Sleeve gastrectomy has emerged as the dominant procedure type in recent years due to its relative technical simplicity and favorable outcomes. The market is supported by a growing network of hospitals and surgical centers across China's tier-1 and tier-2 cities, with data tracked through the Chinese Obesity and Metabolic Surgery Database established by the Chinese Medical Doctor Association. The market benefits from increasing insurance coverage and patient awareness of bariatric surgery as a clinically validated treatment for severe obesity.

• •Valued at approximately $1.2 billion in 2025 with a 14.5% compound annual growth rate
• •Primary procedure types include sleeve gastrectomy, Roux-en-Y gastric bypass, gastric banding, and gastric balloon
• •Market data is tracked through the Chinese Obesity and Metabolic Surgery Database Annual Report 2024

China's rapidly rising obesity rates, driven by urbanization, dietary shifts, and increasingly sedentary lifestyles, constitute the primary demand driver for bariatric surgery. The country has among the highest obesity prevalence growth rates globally, with an expanding population of patients meeting clinical criteria for metabolic and bariatric surgery. Supporting this demand is the growing acceptance of bariatric surgery among Chinese clinicians and patients, improved clinical outcomes data from the national surgical database, and broader insurance reimbursement for obesity-related procedures in select provinces and hospital networks.

• •Rising obesity and overweight prevalence fueled by rapid urbanization and dietary westernization
• •Growing clinical evidence base from the Chinese Obesity and Metabolic Surgery Database supporting procedure efficacy
• •Expanding insurance coverage and hospital network capacity across China's tier-1 and tier-2 cities

The market is segmented by procedure type, device type, and end user. Sleeve gastrectomy commands the largest procedure share, followed by Roux-en-Y gastric bypass, with gastric banding declining in favor of more effective alternatives and gastric balloon procedures growing as a less invasive option. Device categories include stapling devices, suturing devices, gastric bands, and gastric balloons. Regionally, market concentration is highest in eastern and coastal China, particularly Guangdong, Shanghai, Zhejiang, and Jiangsu provinces, where leading hospitals and specialized bariatric centers are concentrated, with tier-2 cities showing the fastest growth as awareness and infrastructure expand.

• •Sleeve gastrectomy is the leading procedure type, followed by Roux-en-Y gastric bypass, with gastric balloon procedures showing notable growth
• •Device categories include stapling devices, suturing devices, adjustable gastric bands, and intragastric balloons
• •Eastern and coastal provinces, especially Guangdong, Shanghai, Zhejiang, and Jiangsu, dominate the market with the highest procedure volumes

What are the recent trends and outlook?

The market is poised to sustain its strong growth trajectory through 2031 and beyond, with the sleeve gastrectomy segment expected to maintain its dominant position and endoscopic bariatric and metabolic therapies gaining attention as minimally invasive alternatives. Digital health tools, including telemedicine consultations for preoperative assessment and postoperative monitoring, are beginning to shape patient pathways. Insurance reimbursement expansion and greater public education on obesity as a disease state will likely accelerate market penetration. The long-term outlook supports continued double-digit growth as China's healthcare infrastructure continues to prioritize metabolic health and chronic disease management.

• •The market is forecast to maintain approximately 14.5% CAGR through 2031, continuing its rapid expansion
• •Endoscopic bariatric therapies and minimally invasive techniques are emerging as complementary alternatives to traditional surgery
• •Insurance reimbursement expansion and growing medical awareness of obesity as a treatable disease are key demand accelerators